Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Teclistamab- and Talquetamab-based Combinations in Newly Diagnosed Transplant-Eligible Multiple Myeloma
2022-001186-12Phase 2Active
- Sponsor
- Heidelberg University
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of teclistamab, talquetamab and daratumumab in multiple myeloma (MM) (2 arms), sponsored by Heidelberg University. Primary endpoint: Incidence and severity of adverse events and serious adverse events. Started Jul 2022; status: active.
02
Drugs
teclistamabtalquetamabdaratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2022-001186-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001186-12.